Merck & Co., Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Merck & Co., Inc. (MRK) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $98.00 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-09.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2011-05-09
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2011-03-31 was $98.00M, a 81.12% decline year-over-year.
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2010-03-31 was $519.00M.
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2010 was $1.09B, a 96.24% increase from fiscal 2009.
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2009 was $558.00M, a 18.98% increase from fiscal 2008.
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2008 was $469.00M, a 64.04% decline from fiscal 2007.
- Merck & Co., Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2007 was $1.30B.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|
| 2011-03-31 | $98.00M 10-Q · filed 2011-05-09 | ||
| 2010-12-31 | $1.09B 10-K · filed 2011-02-28 | ||
| 2010-03-31 | $519.00M 10-Q · filed 2011-05-09 | ||
| 2009-12-31 | $558.00M 10-K · filed 2011-02-28 | $554.60M 10-K · filed 2010-03-01 | |
| 2008-12-31 | $469.00M 10-K · filed 2011-02-28 | $468.40M 10-K · filed 2010-03-01 | |
| 2007-12-31 | $1.30B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |